These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 29407882

  • 21. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
    Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW.
    Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia.
    Wang M, Jiang S, Li B, Parkinson B, Lu J, Tan K, Gu Y, Li S.
    Glob Health Res Policy; 2024 Sep 26; 9(1):38. PubMed ID: 39327612
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH, Barry JC.
    Pediatrics; 2004 Feb 26; 113(2):e95-108. PubMed ID: 14754978
    [Abstract] [Full Text] [Related]

  • 27. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
    Marks D, Thorogood M, Neil HA, Wonderling D, Humphries SE.
    J Public Health Med; 2003 Mar 26; 25(1):47-52. PubMed ID: 12669918
    [Abstract] [Full Text] [Related]

  • 28. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Descamps OS, Van Caenegem O, Hermans MP, Balligand JL, Beauloye C, Bondue A, Carlier S, Castermans E, Chenot F, Claeys M, De Block C, de Leener A, De Meester A, Demeure F, De Raedt H, Desmet W, Elegeert I, Guillaume M, Hoffer E, Kacenelenbogen R, Lancellotti P, Langlois M, Leone A, Mertens A, Paquot N, Vanakker O, Vanoverschelde JL, Verhaegen A, Vermeersch P, Wallemacq C, Rietzschel E, Belgian Atherosclerosis Society/Belgian Lipid Club (BAS/BLC), the Belgian Society of Cardiology (BSC) and the Royal Belgian Society of Laboratory Medicine (RBSLM).
    Atherosclerosis; 2018 Oct 26; 277():369-376. PubMed ID: 30270073
    [Abstract] [Full Text] [Related]

  • 29. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T, Tran A, Webster AC, Klarenbach SW, Gill J, Chadban S, Morton R.
    Am J Kidney Dis; 2020 May 26; 75(5):693-704. PubMed ID: 31810731
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A, Hout BV.
    Clin Ther; 2017 Apr 26; 39(4):771-786.e3. PubMed ID: 28366593
    [Abstract] [Full Text] [Related]

  • 31. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia.
    Ademi Z, Watts GF, Juniper A, Liew D.
    Int J Cardiol; 2013 Sep 10; 167(6):2391-6. PubMed ID: 23490080
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Long-Term Cost-Effectiveness of Case Finding and Mass Screening for Celiac Disease in Children.
    Heijdra Suasnabar J, Meijer CR, Smit L, van Overveld F, Thom H, Keeney E, Mearin ML, van den Akker-van Marle ME.
    Gastroenterology; 2024 Nov 10; 167(6):1129-1140. PubMed ID: 39084268
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals.
    van Kempen BJ, Spronk S, Koller MT, Elias-Smale SE, Fleischmann KE, Ikram MA, Krestin GP, Hofman A, Witteman JC, Hunink MG.
    J Am Coll Cardiol; 2011 Oct 11; 58(16):1690-701. PubMed ID: 21982314
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y, Shimbo T, Tsujii S, Ishii H, Kondo H, Nakamura T, Nagata-Kobayashi S, Fukui T.
    Int J Cardiol; 2007 May 16; 118(1):88-96. PubMed ID: 16949690
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.